Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™

ImmuPharma has also signed a Term Sheet with a US investor for a proposed private placement to fund the clinical trial. The initial instalment of funding consists of a convertible loan of US$2,000,000 plus additional capital of up to US$12,000,000, at the Company’s discretion, subject to certain criteria, over a two year period. Further disclosure on the financial terms of this agreement (the “Agreement”) will be announced following the signature of full agreement anticipated in the next few weeks.

For further details click here